Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTD1 and Capecitabine in HER2-negative Breast Cancer with Brain Metastases
NCT05535413Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of utidelone in breast cancer and brain metastases, sponsored by Hunan Cancer Hospital. Primary endpoint: Central Nervous System Objective Response Rate (RANOBM) at 1 year. Started Jan 2023; status: recruiting.
02
Drugs
utidelone
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT05535413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535413.